Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Avid Radiopharmaceuticals Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

NCT00702143
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
15
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

NCT02079766
View directory record Official record
Conditions
Chronic Traumatic Encephalopathy
Interventions
florbetapir F 18, Flortaucipir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Phoenix, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

NCT01703702
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir (18F)
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

NCT01565330
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2012 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

NCT02016560
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

NCT01503944
View directory record Official record
Conditions
Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease
Interventions
18F-AV-133, 18F-AV-45
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Sun City, Arizona • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2012 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Results available

Flortaucipir PET Imaging in Subjects With FTD

NCT03040713
View directory record Official record
Conditions
Frontotemporal Dementia
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
La Jolla, California • San Francisco, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 1, 2026, 10:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Trial of 18F-AV-133 Positron Emission Tomography (PET)

NCT01515384
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
18F-AV-133
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

NCT01518374
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
Interventions
Florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Sun City, Arizona • Davis, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 1, 2026, 10:05 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807

NCT01733355
View directory record Official record
Conditions
Alzheimers Disease, AD
Interventions
[F18] T807
Radiation
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 1, 2026, 10:05 PM EDT
Recruiting No phase listed Observational

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

NCT03019757
View directory record Official record
Conditions
Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
Interventions
DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, Clinical Assessment
Radiation · Genetic · Procedure + 1 more
Lead sponsor
Douglas Scharre
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 2Phase 3 Interventional

A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

NCT01550484
View directory record Official record
Conditions
Parkinson's Disease, Primary Parkinsonism, Lewy Body Parkinson's Disease
Interventions
18F-AV-133
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Scottsdale, Arizona • Sun City, Arizona • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Tau Screening Study in Patients With Early Symptomatic AD

NCT03322462
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
San Diego, California • Santa Ana, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Results available

Tau Imaging in Professional Fighters

NCT02278354
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

NCT02795780
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan, Whole body PET scan, Florbetapir F 18, Brain MRI
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Cypress, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 1, 2026, 10:05 PM EDT
Terminated Phase 4 Interventional Results available

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

NCT03040427
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

NCT04623242
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 1, 2026, 10:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Online Neuropsychological Test Validation Project With Imaging Pilot

NCT02486250
View directory record Official record
Conditions
Validation of Online Cognitive Testing
Interventions
Validation Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older
Enrollment
982 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls

NCT01710371
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
18F-AV-133, 10% Arginine Hydrochloride-R-Gene 10
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
30 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 12, 2015 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

NCT00855868
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, [11C]-PIB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Sep 1, 2026, 10:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

University of Pittsburgh Brain Health Initiative

NCT04708613
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, PET brain imaging, [C-11]6-OH-BTA-1, [F-18]AV-1451
Diagnostic Test · Drug
Lead sponsor
David Okonkwo, MD, PhD
Other
Eligibility
29 Years to 59 Years · Male only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

NCT00857532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2013 · Synced Sep 1, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation

NCT03901092
View directory record Official record
Conditions
Alzheimer Disease
Interventions
flortaucipir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 1, 2026, 10:05 PM EDT